ORAGENICS INC

For the period ended Sep 30, 2025. Filed Nov 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 7, 2025

OGEN$0.34-3.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

	For the Nine Months Ended September 30,
	2025	2024
Cash flows from operating activities:
Net loss	$(7,555,617)	$(7,218,795)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and closing costs	771,437	-
Stock-based compensation expense	30,525	458,366
Stock-based compensation recapture expense	(86,617)	-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(694,108)	49,951
Operating lease right of use assets	-	9,811
Accounts payable and accrued expenses	1,123,405	131,449
Change in operating lease liabilities	-	(9,811)
Net cash used in operating activities	(6,410,975)	(6,579,029)
Cash flows from financing activities:
Borrowings on short-term notes payable	2,623,399	-
Payments on short-term notes payable	(3,328,528)	(430,283)
Net proceeds from issuance of preferred stock and warrants	15,019,700	-
Net proceeds from issuance of common stock	2,635,330	6,669,860
Net cash provided by financing activities	16,949,901	6,239,577
Net decrease in cash and cash equivalents	10,538,926	(339,452)
Cash and cash equivalents at beginning of period	864,840	3,483,501
Cash and cash equivalents at end of period	$11,403,766	$3,144,049
Supplemental disclosure of cash flow information:
Interest paid	$14,899	$18,859

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.